Immune cell therapy for severe myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy using special immune cells (CAR-NK cells) that may help people whose myasthenia gravis has not improved with standard treatments. It aims to see if these cells can reduce muscle weakness and improve daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of myasthenia gravis that has not improved with standard treatments.
- A blood test must show you have AChR antibodies (a specific marker for this disease).
- You must have significant weakness that affects daily activities (score of 6 or more on a standard scale).
- You must have tried at least two standard treatments (like steroids or other immunosuppressants) and one biologic drug (such as efgartigimod, rituximab, or eculizumab) without enough improvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
Hear when a new Refractory Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.